BGPT: Visualize Data: IC50 comparison niclosamide vs BH-prodrugs 6a-6d across cell lines

Explore by Goal

Quick Analysis Plan Copied

The supplied records confirm the study design (glutathione-responsive Baylis–Hillman niclosamide prodrugs 6a–6d tested by MTT in 67NR, 4T1, MDA-MB-231, MIAPaCa-2, BxPC-3 with n=3 IC50 determination) but contain no extracted numeric IC50 values for 6a–6d, so a direct quantitative comparison cannot yet be plotted .

Long Analysis Plan

Evidence status: exact 6a–6d IC50 values are not in the supplied records

The prodrug paper states IC50 values were derived from three independent MTT experiments across 67NR, 4T1, MDA-MB-231, MIAPaCa-2 and BxPC-3 cells, and that lead prodrug 6b preserves anticancer activity while attenuating niclosamide-driven mitochondrial uncoupling , but the numeric per-compound IC50 table was not captured in the extraction. The only reported niclosamide IC50 in the records is antiviral (0.048 µM in Vero E6, SARS-CoV-2 assay) — a different endpoint and not comparable to the anticancer MTT IC50s .

Analysis plan once values are supplied

Data input: parse a CSV of compound (niclosamide, 6a, 6b, 6c, 6d) × cell line × IC50 (µM) ± 95% CI from the paper's Table.
Primary figure: log-scale grouped bar chart of IC50 per cell line, niclosamide vs 6a–6d, with error bars; secondary heatmap of log2(IC50 ratio vs niclosamide) to flag cell-line-specific resistance shifts.
Statistics: paired comparison of log-IC50 (prodrug vs parent) per line; annotate fold-differences; flag values outside the tested concentration range as censored.
Interpretation guardrails: distinguish reported IC50s from inferred glutathione-release dependence; note n=3, no human breast-cancer line beyond MDA-MB-231, and murine-vs-human species gaps as stated limitations .

What is missing: the actual 6a–6d IC50 numbers (and whether niclosamide-vs-prodrug comparisons used matched assay conditions). Without them, any plot would be fabricated and is deliberately omitted.

Feedback:

Updated: October 26, 2026

Top Data Sources Export MCP

Key Insight

Prodrug IC50 comparisons are only meaningful alongside release kinetics: a prodrug with a higher MTT IC50 may still be superior if its thiol-triggered niclosamide release lowers off-target uncoupling — the trade-off this paper was designed to quantify.

Keep Exploring

How does the glutathione-responsiveness of 6a–6d vary across tumor types with different redox states, and which measured biomarker best predicts prodrug activation in a new cell line?

Do the BH prodrugs preserve niclosamide's antiviral activity in Vero E6 cells, or does masking the phenol alter its Wnt/mt-uncoupling antiviral mechanism?

Analysis Wizard

Loading the prodrug IC50 table to build log-scale cell-line comparisons and fold-change heatmaps once numeric values are supplied, enabling direct niclosamide vs 6a–6d potency ranking.

Hypothesis Graveyard

'Prodrugs are uniformly less potent than niclosamide in vitro.' Unsupportable here: the records report 6b retains anticancer activity but give no per-compound IC50 numbers, so potency rank order is unknown.

Potential Experiments

Rescue test: deplete glutathione with BSO in 67NR and MDA-MB-231 cells, then re-run MTT IC50s for 6a–6d vs niclosamide; a shift toward parent-compound equivalence confirms thiol-dependent activation in each line.

Seahorse OCR dose-response for 6a–6d at equitoxic concentrations; if uncoupling (proton leak rise) is consistently lower than niclosamide at matched growth-inhibition, the therapeutic-index claim is directly quantified per compound.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My extraction pipeline may have missed IC50 values present in the source full text; I default to skepticism over fabricating plausible-looking drug numbers.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

My BGPT

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Evidence status: exact 6a–6d IC50 values are not in the supplied records

Analysis plan once values are supplied

Top Data Sources Export MCP

2. In Vero E6 cells, favipiravir and ivermectin synergistically inhibited SARS-CoV-2, but the combination was only additive in Calu-3 cells; favipiravir with niclosamide or chloroquine also showed only additive effects. [2023]

Ask a Follow-Up

Key Insight

Prodrug IC50 comparisons are only meaningful alongside release kinetics: a prodrug with a higher MTT IC50 may still be superior if its thiol-triggered niclosamide release lowers off-target uncoupling — the trade-off this paper was designed to quantify.

Keep Exploring

How does the glutathione-responsiveness of 6a–6d vary across tumor types with different redox states, and which measured biomarker best predicts prodrug activation in a new cell line?

Do the BH prodrugs preserve niclosamide's antiviral activity in Vero E6 cells, or does masking the phenol alter its Wnt/mt-uncoupling antiviral mechanism?

Analysis Wizard

Loading the prodrug IC50 table to build log-scale cell-line comparisons and fold-change heatmaps once numeric values are supplied, enabling direct niclosamide vs 6a–6d potency ranking.

Hypothesis Graveyard

'Prodrugs are uniformly less potent than niclosamide in vitro.' Unsupportable here: the records report 6b retains anticancer activity but give no per-compound IC50 numbers, so potency rank order is unknown.

Potential Experiments

Rescue test: deplete glutathione with BSO in 67NR and MDA-MB-231 cells, then re-run MTT IC50s for 6a–6d vs niclosamide; a shift toward parent-compound equivalence confirms thiol-dependent activation in each line.

Seahorse OCR dose-response for 6a–6d at equitoxic concentrations; if uncoupling (proton leak rise) is consistently lower than niclosamide at matched growth-inhibition, the therapeutic-index claim is directly quantified per compound.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My extraction pipeline may have missed IC50 values present in the source full text; I default to skepticism over fabricating plausible-looking drug numbers.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Analysis Plan Copied

Long Analysis Plan

Evidence status: exact 6a–6d IC50 values are not in the supplied records

Analysis plan once values are supplied

Top Data Sources ExportMCP

2. In Vero E6 cells, favipiravir and ivermectin synergistically inhibited SARS-CoV-2, but the combination was only additive in Calu-3 cells; favipiravir with niclosamide or chloroquine also showed only additive effects. [2023]

Ask a Follow-Up

Key Insight

Prodrug IC50 comparisons are only meaningful alongside release kinetics: a prodrug with a higher MTT IC50 may still be superior if its thiol-triggered niclosamide release lowers off-target uncoupling — the trade-off this paper was designed to quantify.

Keep Exploring

How does the glutathione-responsiveness of 6a–6d vary across tumor types with different redox states, and which measured biomarker best predicts prodrug activation in a new cell line?

Do the BH prodrugs preserve niclosamide's antiviral activity in Vero E6 cells, or does masking the phenol alter its Wnt/mt-uncoupling antiviral mechanism?

Analysis Wizard

Loading the prodrug IC50 table to build log-scale cell-line comparisons and fold-change heatmaps once numeric values are supplied, enabling direct niclosamide vs 6a–6d potency ranking.

Hypothesis Graveyard

'Prodrugs are uniformly less potent than niclosamide in vitro.' Unsupportable here: the records report 6b retains anticancer activity but give no per-compound IC50 numbers, so potency rank order is unknown.

Potential Experiments

Rescue test: deplete glutathione with BSO in 67NR and MDA-MB-231 cells, then re-run MTT IC50s for 6a–6d vs niclosamide; a shift toward parent-compound equivalence confirms thiol-dependent activation in each line.

Seahorse OCR dose-response for 6a–6d at equitoxic concentrations; if uncoupling (proton leak rise) is consistently lower than niclosamide at matched growth-inhibition, the therapeutic-index claim is directly quantified per compound.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My extraction pipeline may have missed IC50 values present in the source full text; I default to skepticism over fabricating plausible-looking drug numbers.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP